Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001040 · ClinicalTrials.gov registry record · Phase 2

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

A Phase 2 study of HIV Infections, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
300
Enrollment target
10
Study locations

NCT00001040: Completed Phase 2 study of HIV Infections, sponsored by Hoffmann-La Roche.

NCT00001040 is a Phase 2 study of HIV Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 300 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001040, a Phase 2 study of HIV Infections, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target
10
Study locations

Study Summary

PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Saquinavir
  • DRUG Zalcitabine

Study Locations (10)

New York

  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Univ of Rochester Med Ctr - Rochester

Alabama

  • Univ of Alabama at Birmingham - Birmingham

California

  • Stanford Univ Med Ctr - Stanford

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

Illinois

  • Northwestern Univ Med School - Chicago

Ohio

  • Ohio State Univ Hosp - Columbus

Pennsylvania

  • Girard Med Ctr - Philadelphia

Texas

  • Univ TX Galveston Med Branch - Galveston

Trial Details

FieldValue
Enrollment Target 300 participants
Phase Phase 2
Hoffmann-La Roche

909 total trials

What the finished NCT00001040 record still lists

NCT00001040 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.

NCT00001040 lists 10 locations in 9 states (New York, Alabama, California).

Frequently Asked Questions

What is clinical trial NCT00001040 about?

NCT00001040 is a clinical study titled "Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC". PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC. SECONDARY: To investigate the pharmacokinetics and effects on various clinical parame...

What is the current status of trial NCT00001040?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants.

What conditions does trial NCT00001040 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00001040?

The interventions under investigation include: Zidovudine (DRUG), Saquinavir (DRUG), Zalcitabine (DRUG).

Who is sponsoring clinical trial NCT00001040?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001040 being conducted?

This trial has 10 study locations across Alabama, California, Colorado, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00001040's enrollment target sits among peer trials

300 115th of 542 higher than 417 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Related registry views

Source: ClinicalTrials.gov NCT00001040, the US trial registry maintained by the National Library of Medicine. NCT00001040 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.